AIM ImmunoTech Inc. (AIM)

NYSE: AIM · Biological Products, (No Diagnostic Substances) · Ocala, FL · filing with the SEC since 1996

Full chart Alerts Compare

Grade3.3

◀ Past 2.6● Present 3.7▶ Future 3.4

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of AIM ImmunoTech Inc.

Nine metrics read from its own filings, by tense

Headline grade

3.3/10

◀ Past2.625% of the headline

● Present3.735% of the headline

▶ Future3.440% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

2.6/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

1.2/10

Has it survived what it has been through?

7 warning events since 2017; the latest 2025-11-17.

weight 22% of this tense · 12th percentile among 159 sector filers · read for itself

From the record

AIM ImmunoTech Inc.'s filings since 2017 show 7 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 4 times, the latest 2025-06-20); an auditor change (8-K item 4.01, 2 times, the latest 2021-01-22); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2025-11-17) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

3.2/10

What has it actually done, year after year?

-4.2% a year over 10 filed years; profitable in 0 of 10.

weight 45% of this tense · 32nd percentile among 102 sector filers · read for its customers

From the record

AIM ImmunoTech Inc.'s 10 filed years say what it did: revenue went from $161 thousand in fiscal 2011 to $88 thousand in fiscal 2025, down 4.2% a year; it rose in 4 of 9 years; the deepest fall was 80% from fiscal 2017 to fiscal 2025; net income was positive in 0 of 10 of those years (its annual reports).

What it rests on

revenue growth over the filed span-4.2%bottom 21% of its family
the share of years revenue rosebottom 31% of its family
the share of filed years with a profitbottom 31% of its family
the deepest fall from a revenue peak79.9%bottom 47% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

2.7/10

How has it treated the people who own it?

SI estimate 2.7/10, confidence 35 of 100 (one part).

weight 33% of this tense · 27th percentile among 146 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 27% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 146 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: AIM ImmunoTech Inc.'s shareholder treatment is put at 2.7 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 27% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

3.7/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

0.8/10

Is it financially healthy right now?

Leverage 269%: owes 269¢ per asset dollar.

weight 45% of this tense · 8th percentile among 147 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, AIM ImmunoTech Inc.'s shareholders' equity was below zero, so the profit on it is not read. Leverage: it owed about 269 cents per dollar of assets, and net share issuance: its share count grew 189.0% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 6% of its family
the share count against the year beforebottom 9% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

1.5/10

How strong is its position in its industry?

bottom 15% of 102 in its family; net margin -15861.4%.

weight 22% of this tense · 15th percentile among 102 sector filers · read for its customers

From the record

AIM ImmunoTech Inc.'s standing among 102 graded names in its industry family: revenue of $88 thousand in fiscal 2025 ranks in the bottom 7% by size; a net margin of -15861.4% ranks in the bottom 11%; revenue growth of -14.5% a year over the last 3 filed years ranks in the bottom 28% (its annual reports).

What it rests on

revenue against the family$88,000bottom 7% of its family
net margin-15861.4%bottom 11% of its family
three-year revenue growth-14.5%bottom 28% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

9.3/10

What are the people in charge doing?

SI estimate 9.3/10, confidence 35 of 100 (one part).

weight 33% of this tense · 93rd percentile among 137 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the chief executive's years under the title, which ranks in the top 7% of 137 in its family; fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title.
What the record cannot read: Fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title.
How it was reasoned: one part: the chief executive's years on the record, the one part on file, ranked among 137 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: AIM ImmunoTech Inc.'s leadership is put at 9.3 of 10 with a confidence of 35 of 100, because read from one part only, the chief executive's years under the title, which ranks in the top 7% of 137 in its family; fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title. A filing that carries the missing parts replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

3.4/1040% of the headline grade · 3 of 3 filed

Room to expand

as filed

3.3/10

How much room does it have to grow?

bottom 33% of 92 in its family for room to expand.

weight 33% of this tense · 33rd percentile among 92 sector filers · read for itself

From the record

AIM ImmunoTech Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $3 million against debt of $4 million leaves -25.8% of its assets as net cash, bottom 2% of its family; cash from operations less capital spending is -12451.1% of revenue (bottom 7%); research spending of 4459.1% of revenue (top 12%) (its annual report).

What it rests on

cash less debt against assets-25.8%bottom 2% of its family
cash from operations less capital spending against revenue-12451.1%bottom 7% of its family
research spending against revenue4459.1%top 12% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

3.7/10

What could actually drive growth from here?

bottom 37% of 100 in its family for growth drivers.

weight 45% of this tense · 37th percentile among 100 sector filers · read for its customers

From the record

AIM ImmunoTech Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -14.5% a year over the last three filed years against -4.2% over all 10, slowing (bottom 47% of its family); the newest year grew -48.3% (bottom 12%); research spending grew -17.5% a year (bottom 16%); capital spending grew -4.9% a year (top 28%) (its annual reports). AIM ImmunoTech Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span-10.3 points a yearbottom 47% of its family
the newest year's revenue growth-48.3%bottom 12% of its family
three-year growth of research spending-17.5%bottom 16% of its family
three-year growth of capital spending-4.9%top 28% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

3.0/10

Did its newest year beat what its own record pointed to?

bottom 30% of 72 in its family for expectations against reality.

weight 22% of this tense · 30th percentile among 72 sector filers · read for its shareholders

From the record

AIM ImmunoTech Inc.'s newest year against its own record: revenue of $88 thousand in fiscal 2025 came in 52.9% below the $187 thousand its prior three years' pace pointed to (bottom 13% of its family); net income of $14 million against a prior three-year average of $22 million (top 34%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 9%) (its annual reports).

What it rests on

revenue against the prior three years' pace-52.9%bottom 13% of its family
net income against the prior three years' average+36%top 34% of its family
net margin against its prior averagedown more than 100 pointsbottom 9% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton AIM · research, not advice